EU Approves Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment

by Kathy Jones on  August 16, 2011 at 8:22 PM Heart Disease News
RSS Email Print This Page Comment bookmark
Font : A-A+

The Mitroflow Aortic Pericardial Heart Valve with Phospholipid Reduction Treatment (PRT) has received the European CE Mark approval, Sorin Group has announced.
 EU Approves Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment
EU Approves Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment

The PRT component of the valve is aimed at relieving calcification of the device and increase its durability. A released statement by Sorin said that phospholipids play a key role in the calcification process of biosprotheses.

"The addition of PRT to the Mitroflow bioprosthesis will help mitigate potential calcification and possibly further improve the tissue valve's clinically proven outstanding durability," it added.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Heart Healthy Heart Statins Mitral Valve Prolapse Aortic Valve Stenosis Pericarditis Bicuspid Aortic Valve 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive